Blue Jet Healthcare Ltd
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.[1]
- Market Cap ₹ 6,326 Cr.
- Current Price ₹ 364
- High / Low ₹ 433 / 319
- Stock P/E 45.8
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 57.3 %
- ROE 51.1 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Operating Profit |
OPM % |
Interest |
Depreciation |
Profit before tax |
Tax % |
EPS in Rs |
Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | |
---|---|---|
538 | 499 | |
324 | 293 | |
Operating Profit | 214 | 206 |
OPM % | 40% | 41% |
6 | 4 | |
Interest | 7 | 5 |
Depreciation | 18 | 20 |
Profit before tax | 194 | 185 |
Tax % | 25% | 26% |
145 | 136 | |
EPS in Rs | 24,141.67 | 1,396.49 |
Dividend Payout % | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -7% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -4% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | 51% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | |
---|---|---|
Equity Capital | 1 | 10 |
Reserves | 201 | 330 |
79 | 53 | |
95 | 143 | |
Total Liabilities | 375 | 536 |
107 | 139 | |
CWIP | 2 | 3 |
Investments | 34 | 37 |
232 | 358 | |
Total Assets | 375 | 536 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | |
---|---|---|
123 | 129 | |
-45 | -51 | |
-72 | -28 | |
Net Cash Flow | 5 | 51 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2020 | Mar 2021 | |
---|---|---|
Debtor Days | 80 | 105 |
Inventory Days | 120 | 253 |
Days Payable | 90 | 128 |
Cash Conversion Cycle | 110 | 231 |
Working Capital Days | 78 | 104 |
ROCE % | 57% |
Documents
Announcements
- Reg 40(10) For The Year Ended March 31, 2024 17 Apr
- Compliance Certificate For The Year Ended March 31, 2024. 11 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Apr
- Closure of Trading Window 27 Mar
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
14 Feb - Of Transcript of the Earnings Call with Analyst/Investors on Financial Results for the third quarter and nine months ended December, 2023
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
Product Portfolio
A) Contrast media intermediates (70.5% of FY23 revenue)[1]
Contrast media are agents used in medical imaging to enhance visibility of body tissues under X-rays, computed tomography (CT), magnetic resonance imaging (MRI), or ultrasound.